Ubiquigent

Ubiquigent’s scientific and business interests have a clear focus; namely the ubiquitin, ubiquitin-like, and integrated signalling systems. They have established their scientific and business credentials with both academic researchers undertaking fundamental scientific discovery and pharmaceutical and biotechnology company scientists exploring the potential of ubiquitin cascade-focused drug discovery. They provide access to the necessary expertise, Drug Discovery Services, high quality Research Tools and Chemistry required to support commercial and academic partners in pursuing ubiquitin system-focused drug discovery programmes, and in undertaking basic research.

Ubiquigent benefits from high calibre backing including from private US investors, the UK Medical Research Council, and the University of Dundee. The Company’s headquarters and laboratory operations are based in the UK and are located in a state-of-the-art facility adjacent to the MRC Protein Phosphorylation and Ubiquitylation Unit at the University of Dundee (both founded by Professor Sir Philip Cohen). In addition to Ubiquigent’s own facilities and capabilities, such proximity provides ready access to a huge range of additional scientific expertise (1,000+ life-science researchers on site), technological competencies, and assay and analytical platforms. Ubiquigent staff have a wealth of scientific experience, technological competencies and commercial expertise, gained from within academia, the life science research reagents and services sector, and the pharmaceutical industry.  This wealth of knowledge enables the company to offer a level of understanding and service to its customers and clients worldwide that few companies may match.

Ubiquigent and the University of Dundee have a long standing relationship in the ubiquitin field. Ubiquigent are the University’s exclusive commercialisation partner for all ubiquitin related Research Tools developed by the University.